1
Clinical Trials associated with CD19 targeted CAR T Cell Therapy(H. Lee Moffitt Cancer Center and Research Institute) / Active, not recruitingPhase 2IIT Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination With Pneumococcal 13-valent Conjugate Vaccine Before and After CD19-targeted CAR T-cell Immunotherapy
The purpose of the study is to evaluate whether receiving the pneumococcal 13-valent conjugate vaccine (PCV13) before and after CD19-targeted CAR T cell therapy will optimize cellular and humoral immunity to pneumococcus.
100 Clinical Results associated with CD19 targeted CAR T Cell Therapy(H. Lee Moffitt Cancer Center and Research Institute)
100 Translational Medicine associated with CD19 targeted CAR T Cell Therapy(H. Lee Moffitt Cancer Center and Research Institute)
100 Patents (Medical) associated with CD19 targeted CAR T Cell Therapy(H. Lee Moffitt Cancer Center and Research Institute)
100 Deals associated with CD19 targeted CAR T Cell Therapy(H. Lee Moffitt Cancer Center and Research Institute)